398 related articles for article (PubMed ID: 21610513)
1. Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial.
Matsuzaki M; Ogihara T; Umemoto S; Rakugi H; Matsuoka H; Shimada K; Abe K; Suzuki N; Eto T; Higaki J; Ito S; Kamiya A; Kikuchi K; Suzuki H; Tei C; Ohashi Y; Saruta T;
J Hypertens; 2011 Aug; 29(8):1649-59. PubMed ID: 21610513
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy for hypertension in the elderly: a sub-analysis of the Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) Trial.
Ogihara T; Matsuzaki M; Umemoto S; Rakugi H; Matsuoka H; Shimada K; Higaki J; Ito S; Kamiya A; Suzuki H; Ohashi Y; Shimamoto K; Saruta T;
Hypertens Res; 2012 Apr; 35(4):441-8. PubMed ID: 22278623
[TBL] [Abstract][Full Text] [Related]
3. Comparison of combination therapies, including the angiotensin receptor blocker olmesartan and either a calcium channel blocker or a thiazide diuretic, in elderly patients with hypertension.
Kato J; Yokota N; Tamaki N; Kariya S; Kita T; Ayabe T; Eto T; Kitamura K
Hypertens Res; 2011 Mar; 34(3):331-5. PubMed ID: 21124326
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy for hypertension in patients with CKD: a subanalysis of the Combination Therapy of Hypertension to Prevent Cardiovascular Events trial.
Rakugi H; Ogihara T; Umemoto S; Matsuzaki M; Matsuoka H; Shimada K; Higaki J; Ito S; Kamiya A; Suzuki H; Ohashi Y; Shimamoto K; Saruta T;
Hypertens Res; 2013 Nov; 36(11):947-58. PubMed ID: 23864054
[TBL] [Abstract][Full Text] [Related]
5. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients.
Ogawa H; Kim-Mitsuyama S; Matsui K; Jinnouchi T; Jinnouchi H; Arakawa K;
Am J Med; 2012 Oct; 125(10):981-90. PubMed ID: 22503610
[TBL] [Abstract][Full Text] [Related]
7. Effects of Calcium-Channel Blocker Benidipine-Based Combination Therapy on Cardiac Events - Subanalysis of the COPE Trial.
Umemoto S; Ogihara T; Matsuzaki M; Rakugi H; Shimada K; Kawana M; Kario K; Ohashi Y; Saruta T;
Circ J; 2018 Jan; 82(2):457-463. PubMed ID: 28867690
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension.
Ishimitsu T; Numabe A; Masuda T; Akabane T; Okamura A; Minami J; Matsuoka H
Hypertens Res; 2009 Nov; 32(11):962-8. PubMed ID: 19696778
[TBL] [Abstract][Full Text] [Related]
9. Effects of a benidipine-based combination therapy on the risk of stroke according to stroke subtype: the COPE trial.
Umemoto S; Ogihara T; Rakugi H; Matsumoto M; Kitagawa K; Shimada K; Higaki J; Ito S; Suzuki H; Ohashi Y; Saruta T; Matsuzaki M;
Hypertens Res; 2013 Dec; 36(12):1088-95. PubMed ID: 23985703
[TBL] [Abstract][Full Text] [Related]
10. Effects of calcium channel blocker-based combinations on intra-individual blood pressure variability: post hoc analysis of the COPE trial.
Umemoto S; Ogihara T; Matsuzaki M; Rakugi H; Ohashi Y; Saruta T;
Hypertens Res; 2016 Jan; 39(1):46-53. PubMed ID: 26490089
[TBL] [Abstract][Full Text] [Related]
11. Effects of calcium channel blocker benidipine-based combination therapy on target blood pressure control and cardiovascular outcome: a sub-analysis of the COPE trial.
Umemoto S; Ogihara T; Matsuzaki M; Rakugi H; Ohashi Y; Saruta T;
Hypertens Res; 2017 Apr; 40(4):376-384. PubMed ID: 27904156
[TBL] [Abstract][Full Text] [Related]
12. Effects of an Antihypertensive Combination in Japanese Hypertensive Outpatients Based on the Long-acting Calcium Channel Blocker Benidipine on Vascular and Renal Events: A Sub-analysis of the COPE Trial.
Umemoto S; Ogihara T; Matsuzaki M; Rakugi H; Shimada K; Hayashi K; Makino H; Ohashi Y; Saruta T
Curr Hypertens Rev; 2020; 16(3):238-245. PubMed ID: 31995012
[TBL] [Abstract][Full Text] [Related]
13. One-year results of an open-label study on antiproteinuric effect of benidipine in elderly patients with chronic kidney disease.
Tomino Y; Shimizu Y; Hamada C; Kurusu A; Ohsawa I; Suzuki Y; Tsuge T; Io H; Kobayashi N; Takeda Y; Asanuma K; Tanaka Y; Suzuki H; Nakata J; Takara K; Horikoshi S
J Nephrol; 2011; 24(6):756-63. PubMed ID: 21360472
[TBL] [Abstract][Full Text] [Related]
14. Renoprotective effect and cost-effectiveness of using benidipine, a calcium channel blocker, to lower the dose of angiotensin receptor blocker in hypertensive patients with albuminuria.
Saito F; Fujita H; Takahashi A; Ichiyama I; Harasawa S; Oiwa K; Takahashi N; Otsuka Y; Uchiyama T; Kanmatsuse K; Kushiro T
Hypertens Res; 2007 Jan; 30(1):39-47. PubMed ID: 17460370
[TBL] [Abstract][Full Text] [Related]
15. The development of new-onset type 2 diabetes associated with choosing a calcium channel blocker compared to a diuretic or beta-blocker.
Kuti EL; Baker WL; White CM
Curr Med Res Opin; 2007 Jun; 23(6):1239-44. PubMed ID: 17559720
[TBL] [Abstract][Full Text] [Related]
16. Effect of antihypertensive treatment on cardiovascular events in elderly hypertensive patients: Japan's Benidipine Research on Antihypertensive Effects in the Elderly (J-BRAVE).
Saito I; Suzuki H; Kageyama S; Saruta T
Clin Exp Hypertens; 2011; 33(2):133-40. PubMed ID: 21269056
[TBL] [Abstract][Full Text] [Related]
17. [COPE trial].
Umemoto S; Kamiya A; Matsuzaki M; Ogihara T
Nihon Rinsho; 2006 Aug; 64 Suppl 6():470-4. PubMed ID: 16981580
[No Abstract] [Full Text] [Related]
18. Comparison of the antiproteinuric effects of the calcium channel blockers benidipine and amlodipine administered in combination with angiotensin receptor blockers to hypertensive patients with stage 3-5 chronic kidney disease.
Abe M; Okada K; Maruyama T; Maruyama N; Matsumoto K
Hypertens Res; 2009 Apr; 32(4):270-5. PubMed ID: 19262495
[TBL] [Abstract][Full Text] [Related]
19. [Assessment of antihypertensive monotherapies effectiveness by home blood pressure self-measurement in hypertensive patients].
Hanon O; Laroche P; Vidal JS; Pannier B; Postel-Vinay N; Vaisse B; Girerd X
Ann Cardiol Angeiol (Paris); 2012 Jun; 61(3):218-23. PubMed ID: 22695025
[TBL] [Abstract][Full Text] [Related]
20. Rationale, study design and implementation of the COLM study: the combination of OLMesartan and calcium channel blocker or diuretic in high-risk elderly hypertensive patients.
Ogihara T; Saruta T; Rakugi H; Shimamoto K; Ito S; Matsuoka H; Horiuchi M; Imaizumi T; Takishita S; Higaki J; Katayama S; Saito I; Shimada K;
Hypertens Res; 2009 Feb; 32(2):163-7. PubMed ID: 19262477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
